404 related articles for article (PubMed ID: 26004871)
1. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells.
Johansson D; Andersson C; Moharer J; Johansson A; Behnam-Motlagh P
Br J Cancer; 2010 Jan; 102(2):383-91. PubMed ID: 20010943
[TBL] [Abstract][Full Text] [Related]
4. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
5. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Gramatzki D; Herrmann C; Happold C; Becker KA; Gulbins E; Weller M; Tabatabai G
PLoS One; 2013; 8(5):e63527. PubMed ID: 23667632
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
Roh JL; Kim EH; Park JY; Kim JW
Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
[TBL] [Abstract][Full Text] [Related]
7. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
8. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
10. Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (gb3) for reversal of multidrug resistance to cancer chemotherapy.
Behnam-Motlagh P; Tyler A; Grankvist K; Johansson A
Toxins (Basel); 2010 Oct; 2(10):2467-77. PubMed ID: 22069561
[TBL] [Abstract][Full Text] [Related]
11. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a cisplatin-induced multidrug resistance cell line SK-Hep1/DDP.
Zhou Y; Ling XL
Chin J Cancer; 2010 Feb; 29(2):167-71. PubMed ID: 20109345
[TBL] [Abstract][Full Text] [Related]
13. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
[TBL] [Abstract][Full Text] [Related]
14. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis.
Johansson D; Kosovac E; Moharer J; Ljuslinder I; Brännström T; Johansson A; Behnam-Motlagh P
BMC Cancer; 2009 Feb; 9():67. PubMed ID: 19245689
[TBL] [Abstract][Full Text] [Related]
15. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.
Lavie Y; Cao Ht; Volner A; Lucci A; Han TY; Geffen V; Giuliano AE; Cabot MC
J Biol Chem; 1997 Jan; 272(3):1682-7. PubMed ID: 8999846
[TBL] [Abstract][Full Text] [Related]
16. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
[TBL] [Abstract][Full Text] [Related]
17. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.
Gouazé-Andersson V; Yu JY; Kreitenberg AJ; Bielawska A; Giuliano AE; Cabot MC
Biochim Biophys Acta; 2007 Dec; 1771(12):1407-17. PubMed ID: 18035065
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
Norris-Cervetto E; Callaghan R; Platt FM; Dwek RA; Butters TD
J Biol Chem; 2004 Sep; 279(39):40412-8. PubMed ID: 15263008
[TBL] [Abstract][Full Text] [Related]
20. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells.
Zhao L; Zhang W; Zhang F
Phytother Res; 2021 Jan; 35(1):278-288. PubMed ID: 32779800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
